Drug major Glenmark Pharmaceuticals today came out with positive findings from phase 2a study of GBR 830, an investigational monoclonal anti-body in atopic dermatitis (AD), a chronic skin disease.
It now plans to initiate a phase 2b trial in the first half of 2018.
"The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in adults with moderate-to-severe AD with history of inadequate response to topical therapies," Glenmark Pharma said in a BSE filing.
Also Read
It further said: "Based on the results of this Phase 2a study, Glenmark is firmly committed to advancing GBR 830 for patients with AD and plans to initiate a Phase 2b trial in the first half of calendar year 2018."
Glenmark Pharma President and Chief Medical Officer Fred Grossman said atopic dermatitis can have a severe impact on quality of life and there is an unmet need for safe and more durable therapies for people suffering from the disease.
In the Phase 2a study, a total of 31 patients were evaluated.
Disclaimer: No Business Standard Journalist was involved in creation of this content
